AYAL Capital Advisors Ltd Sells 115,635 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

AYAL Capital Advisors Ltd reduced its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 539,871 shares of the medical device company's stock after selling 115,635 shares during the period. Orthofix Medical comprises approximately 2.5% of AYAL Capital Advisors Ltd's portfolio, making the stock its 2nd largest position. AYAL Capital Advisors Ltd owned approximately 1.41% of Orthofix Medical worth $9,426,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of OFIX. R Squared Ltd acquired a new position in shares of Orthofix Medical in the 4th quarter valued at $50,000. KLP Kapitalforvaltning AS acquired a new position in Orthofix Medical in the fourth quarter valued at $112,000. Tower Research Capital LLC TRC grew its holdings in shares of Orthofix Medical by 120.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock worth $148,000 after purchasing an additional 4,627 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Orthofix Medical during the fourth quarter worth about $234,000. Finally, Inceptionr LLC purchased a new stake in shares of Orthofix Medical in the 4th quarter valued at about $279,000. Institutional investors and hedge funds own 89.76% of the company's stock.

Insider Buying and Selling at Orthofix Medical

In related news, insider Jorge Andres Cedron sold 3,816 shares of Orthofix Medical stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $13.31, for a total transaction of $50,790.96. Following the completion of the transaction, the insider now directly owns 42,500 shares of the company's stock, valued at approximately $565,675. The trade was a 8.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Lucas Vitale sold 4,287 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total value of $71,164.20. Following the sale, the insider now owns 135,317 shares in the company, valued at approximately $2,246,262.20. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,475 shares of company stock valued at $128,065. Corporate insiders own 2.60% of the company's stock.

Analyst Upgrades and Downgrades

OFIX has been the topic of several research analyst reports. StockNews.com lowered Orthofix Medical from a "buy" rating to a "hold" rating in a research report on Wednesday. Canaccord Genuity Group reiterated a "buy" rating and issued a $24.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, Roth Mkm reiterated a "buy" rating and set a $22.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.33.

Orthofix Medical Price Performance

Shares of OFIX traded up $0.59 during trading hours on Thursday, reaching $12.61. The company had a trading volume of 170,080 shares, compared to its average volume of 259,536. The company has a market capitalization of $492.07 million, a price-to-earnings ratio of -4.03 and a beta of 0.87. Orthofix Medical Inc. has a 12-month low of $10.50 and a 12-month high of $20.73. The firm has a 50 day simple moving average of $15.06 and a 200-day simple moving average of $16.96. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.